C12N2710/10011 - CPC Classification Index

ClassID:

109612 ⎘

C12N2710/10011 - CPC Classification

Classification description:

dsDNA viruses; Details Adenoviridae

Sub-classes:

C12N2710/10021 » Viruses as such, e.g. new isolates, mutants or their genomic sequences 77
C12N2710/10022 » New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes 69
C12N2710/10023 » Virus like particles [VLP] 14
C12N2710/10031 » Uses of virus other than therapeutic or vaccine, e.g. disinfectant 5
C12N2710/10032 » Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent 120
C12N2710/10033 » Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory 29
C12N2710/10034 » Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein 98
C12N2710/10041 » Use of virus, viral particle or viral elements as a vector 101
C12N2710/10051 » Methods of production or purification of viral material 69
C12N2710/10061 » Methods of inactivation or attenuation 5
C12N2710/10071 » Demonstrated in vivo effect 68
C12N2710/10088 » For redistribution 1
C12N2710/10111 » Atadenovirus, e.g. ovine adenovirus D 2
C12N2710/10211 » Aviadenovirus, e.g. fowl adenovirus A 0
C12N2710/10311 » Mastadenovirus, e.g. human or simian adenoviruses 7

Recent Application in this class:

20250382638

2025-12-18

EXOGENOUS GENE EXPRESSION IN RECOMBINANT ADENOVIRUS FOR MINIMAL IMPACT ON VIRAL KINETICS

20250092105

2025-03-20

GRANULIN/EPITHELIN MODULES AND COMBINATIONS THEREOF TO TREAT NEURODEGENERATIVE DISEASE

20240016914

2024-01-18

Targeted neoepitope vectors and methods therefor

20230323395

2023-10-12

METHODS AND COMPOSITIONS FOR THE PRODUCTION OF ADENO-ASSOCIATED VIRUS

20230088476

2023-03-23

Exogenous gene expression in recombinant adenovirus for minimal impact on viral kinetics

20220325258

2022-10-13

METHODS AND COMPOSITIONS FOR CELL AND TISSUE REJUVENATION

20210087583

2021-03-25

Minigene for the treatment of Usher syndrome type 2a and USH2A-associated retinitis pigmentosa.

20210047649

2021-02-18

CRISPR/CAS ALL-IN-TWO VECTOR SYSTEMS FOR TREATMENT OF DMD

20210046114

2021-02-18

HPV IMMUNOTHERAPY

#10

20200325492

2020-10-15

Exogenous gene expression in recombinant adenovirus for minimal impact on viral kinetics

#11

20200054730

2020-02-20

Targeted neoepitope vectors and methods therefor

#12

20180355379

2018-12-13

Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics

#13

20180305665

2018-10-25

Method for enrichment and expansion of virus antigen-specific T cells

#14

20180080045

2018-03-22

Canine adenovirus vectors

#15

15130041

2018-11-20

TAA/ecdCD40L oncolytic virus